Dialysis therapy: Concept evolution and update

Research output: Contribution to journalReview article

Abstract

End-stage renal disease (ESRD) is the most severe stage of chronic kidney disease. Dialysis, one of the renal replacement therapy, provides life-saving therapy for the patients with ESRD. It is paramount to improve disease outcome and quality of life while performing dialysis. According to previous studies among hemodialysis (HD) patients, the results didn't support to initiate HD at specific timing (early vs late initiation). In addition, there was no clear evidence to improve survival rate through an increase of HD dose, intensity or frequency. Although dialysate composition carries weight to the cardiovascular system, the relationships between various dialysate compositions and patient outcomes remain to be elucidated. For peritoneal dialysis (PD), peritoneal dialysis solutions other than glucose-based ones, Icodextrin or biocompatible peritoneal dialysis solutions, may be benefit for fluid control and preservation of peritoneal membrane function, and preventing encapsulating peritoneal sclerosis. About the comparison between dialysis modalities (PD vs HD), there is no significant difference between HD and PD in terms of life expectancy, quality of life and quality-adjusted life expectancy when analyzing the Taiwanese National Insurance Database and dialysis-related cohorts; however, PD is more cost-effective than HD.

Original languageEnglish
Pages (from-to)86-95
Number of pages10
JournalJournal of Internal Medicine of Taiwan
Volume30
Issue number2
DOIs
Publication statusPublished - 2019 Apr 1

Fingerprint

Peritoneal Dialysis
Renal Dialysis
Dialysis
Dialysis Solutions
Quality of Life
Life Expectancy
Chronic Kidney Failure
Therapeutics
Peritoneal Fibrosis
Renal Replacement Therapy
Cardiovascular System
Insurance
Chronic Renal Insufficiency
Survival Rate
Databases
Weights and Measures
Costs and Cost Analysis
Glucose
Membranes

All Science Journal Classification (ASJC) codes

  • Internal Medicine

Cite this

@article{4d91454ba6534ce69f0396a89591727b,
title = "Dialysis therapy: Concept evolution and update",
abstract = "End-stage renal disease (ESRD) is the most severe stage of chronic kidney disease. Dialysis, one of the renal replacement therapy, provides life-saving therapy for the patients with ESRD. It is paramount to improve disease outcome and quality of life while performing dialysis. According to previous studies among hemodialysis (HD) patients, the results didn't support to initiate HD at specific timing (early vs late initiation). In addition, there was no clear evidence to improve survival rate through an increase of HD dose, intensity or frequency. Although dialysate composition carries weight to the cardiovascular system, the relationships between various dialysate compositions and patient outcomes remain to be elucidated. For peritoneal dialysis (PD), peritoneal dialysis solutions other than glucose-based ones, Icodextrin or biocompatible peritoneal dialysis solutions, may be benefit for fluid control and preservation of peritoneal membrane function, and preventing encapsulating peritoneal sclerosis. About the comparison between dialysis modalities (PD vs HD), there is no significant difference between HD and PD in terms of life expectancy, quality of life and quality-adjusted life expectancy when analyzing the Taiwanese National Insurance Database and dialysis-related cohorts; however, PD is more cost-effective than HD.",
author = "Kuo, {Yi Ting} and Chia-Chun Lee and Junne-Ming Sung",
year = "2019",
month = "4",
day = "1",
doi = "10.6314/JIMT.201904_30(2).05",
language = "English",
volume = "30",
pages = "86--95",
journal = "Journal of Internal Medicine of Taiwan",
issn = "1016-7390",
publisher = "Society of Internal Medicine of Taiwan",
number = "2",

}

Dialysis therapy : Concept evolution and update. / Kuo, Yi Ting; Lee, Chia-Chun; Sung, Junne-Ming.

In: Journal of Internal Medicine of Taiwan, Vol. 30, No. 2, 01.04.2019, p. 86-95.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Dialysis therapy

T2 - Concept evolution and update

AU - Kuo, Yi Ting

AU - Lee, Chia-Chun

AU - Sung, Junne-Ming

PY - 2019/4/1

Y1 - 2019/4/1

N2 - End-stage renal disease (ESRD) is the most severe stage of chronic kidney disease. Dialysis, one of the renal replacement therapy, provides life-saving therapy for the patients with ESRD. It is paramount to improve disease outcome and quality of life while performing dialysis. According to previous studies among hemodialysis (HD) patients, the results didn't support to initiate HD at specific timing (early vs late initiation). In addition, there was no clear evidence to improve survival rate through an increase of HD dose, intensity or frequency. Although dialysate composition carries weight to the cardiovascular system, the relationships between various dialysate compositions and patient outcomes remain to be elucidated. For peritoneal dialysis (PD), peritoneal dialysis solutions other than glucose-based ones, Icodextrin or biocompatible peritoneal dialysis solutions, may be benefit for fluid control and preservation of peritoneal membrane function, and preventing encapsulating peritoneal sclerosis. About the comparison between dialysis modalities (PD vs HD), there is no significant difference between HD and PD in terms of life expectancy, quality of life and quality-adjusted life expectancy when analyzing the Taiwanese National Insurance Database and dialysis-related cohorts; however, PD is more cost-effective than HD.

AB - End-stage renal disease (ESRD) is the most severe stage of chronic kidney disease. Dialysis, one of the renal replacement therapy, provides life-saving therapy for the patients with ESRD. It is paramount to improve disease outcome and quality of life while performing dialysis. According to previous studies among hemodialysis (HD) patients, the results didn't support to initiate HD at specific timing (early vs late initiation). In addition, there was no clear evidence to improve survival rate through an increase of HD dose, intensity or frequency. Although dialysate composition carries weight to the cardiovascular system, the relationships between various dialysate compositions and patient outcomes remain to be elucidated. For peritoneal dialysis (PD), peritoneal dialysis solutions other than glucose-based ones, Icodextrin or biocompatible peritoneal dialysis solutions, may be benefit for fluid control and preservation of peritoneal membrane function, and preventing encapsulating peritoneal sclerosis. About the comparison between dialysis modalities (PD vs HD), there is no significant difference between HD and PD in terms of life expectancy, quality of life and quality-adjusted life expectancy when analyzing the Taiwanese National Insurance Database and dialysis-related cohorts; however, PD is more cost-effective than HD.

UR - http://www.scopus.com/inward/record.url?scp=85066618806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066618806&partnerID=8YFLogxK

U2 - 10.6314/JIMT.201904_30(2).05

DO - 10.6314/JIMT.201904_30(2).05

M3 - Review article

AN - SCOPUS:85066618806

VL - 30

SP - 86

EP - 95

JO - Journal of Internal Medicine of Taiwan

JF - Journal of Internal Medicine of Taiwan

SN - 1016-7390

IS - 2

ER -